{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:08:27Z","timestamp":1792667307407,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012688","name":"University of Rostock","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.molmet.2026.102402","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:35:52Z","timestamp":1781714152000},"page":"102402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells"],"prefix":"10.1016","volume":"110","author":[{"given":"Patricia","family":"Maass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nares","family":"Trakooljul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieder","family":"Hadlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Sekora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Murua Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Wimmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-7072","authenticated-orcid":false,"given":"Anna","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2026.102402_bib1","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.molmet.2026.102402_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-022-01093-3","article-title":"Effective tumor cell abrogation via venetoclax-mediated BCL-2 inhibition in KMT2A-Rearranged acute B-Lymphoblastic leukemia","volume":"8","author":"Richter","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.molmet.2026.102402_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.molmet.2026.102402_bib4","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-Specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.molmet.2026.102402_bib5","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.molmet.2026.102402_bib6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","article-title":"A phase 1\/2 study of Mini-Hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Short","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.molmet.2026.102402_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.molmet.2026.102402_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.molmet.2026.102402_bib9","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-Day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.molmet.2026.102402_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.molmet.2026.102402_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-018-0607-3","article-title":"Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements","volume":"11","author":"Roolf","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.molmet.2026.102402_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jgg.2020.04.006","article-title":"DNA methyltransferases in hematological malignancies","volume":"47","author":"Hoang","year":"2020","journal-title":"J Genet Genomics"},{"key":"10.1016\/j.molmet.2026.102402_bib13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/leu.2008.397","article-title":"The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells","volume":"23","author":"Flotho","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.molmet.2026.102402_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13050","article-title":"Safety and clinical activity of 5-Aza-2\u2019-Deoxycytidine (Decitabine) with or without Hyper-CVAD in relapsed\/refractory acute lymphocytic leukaemia","volume":"167","author":"Benton","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.molmet.2026.102402_bib15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ajh.23778","article-title":"A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"89","author":"Burke","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.molmet.2026.102402_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-Cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.molmet.2026.102402_bib17","article-title":"Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-Rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy","author":"Cheung","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.molmet.2026.102402_bib18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/1878-0261.13792","article-title":"KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells","volume":"19","author":"Brock","year":"2025","journal-title":"Mol Oncol"},{"key":"10.1016\/j.molmet.2026.102402_bib19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.molmet.2026.102402_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"10.1016\/j.molmet.2026.102402_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12885-019-5411-0","article-title":"Combined casein kinase II inhibition and epigenetic modulation in acute B-Lymphoblastic leukemia","volume":"19","author":"Richter","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molmet.2026.102402_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-020-6650-9","article-title":"Influence of Casein Kinase II inhibitor CX-4945 on BCL6-Mediated apoptotic signaling in B-ALL in vitro and in vivo","volume":"20","author":"Richter","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molmet.2026.102402_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells11010150","article-title":"The molecular subtype of adult acute lymphoblastic leukemia samples determines the engraftment site and proliferation kinetics in patient-derived xenograft models","volume":"11","author":"Richter","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.molmet.2026.102402_bib24","unstructured":"Marques de Almeida, F.; Peltzer, A.; Sturm, G.; Heylf; Botvinnik, O.; Bot, N.; He, D.; Trummer, N.; Menden, K.; Talbot, A.; et al. Nf-Core\/Scrnaseq: 4.0.0 2025."},{"key":"10.1016\/j.molmet.2026.102402_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.molmet.2026.102402_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.molmet.2026.102402_bib27","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.molmet.2026.102402_bib28","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/cpz1.90","article-title":"Gene set knowledge discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr Protoc"},{"key":"10.1016\/j.molmet.2026.102402_bib29","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-Sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.molmet.2026.102402_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41420-024-01800-2","article-title":"Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.molmet.2026.102402_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40164-024-00489-4","article-title":"Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia","volume":"13","author":"Feng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.molmet.2026.102402_bib32","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1038\/s41467-025-59531-6","article-title":"CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition","volume":"16","author":"Garcia-Gimenez","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.molmet.2026.102402_bib33","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1535-7163.MCT-13-0137","article-title":"Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-Azacytidine and 5-Aza-2\u2019-Deoxycytidine in solid tumor cells","volume":"12","author":"Venturelli","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.molmet.2026.102402_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neo.2014.05.009","article-title":"5-Aza-2\u2019-Deoxycytidine-Mediated c-Myc down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia","volume":"16","author":"Grandjenette","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.molmet.2026.102402_bib35","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1158\/0008-5472.CAN-23-2804","article-title":"BCL-XL targeting to induce apoptosis and to eliminate chemotherapy-induced senescent tumor cells: from navitoclax to platelet-sparing BCL-XL PROTACs","volume":"83","author":"Skwarska","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.molmet.2026.102402_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-024-06864-7","article-title":"Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by Co-Targeting oxidative phosphorylation","volume":"15","author":"Enzenm\u00fcller","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.molmet.2026.102402_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.molmet.2026.102402_bib38","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.molmet.2026.102402_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.molmet.2026.102402_bib40","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine Disrupts energy metabolism and targets leukemia stem cells in patients with Acute Myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.molmet.2026.102402_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-143200","article-title":"Venetoclax inhibition of pyrimidine synthesis guides methods for integration with decitabine or 5-Azacytidine that are non-myelosuppressive","volume":"136","author":"Gu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.molmet.2026.102402_bib42","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","article-title":"The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML","volume":"234","author":"Nguyen","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.molmet.2026.102402_bib43","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","author":"Jin","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877826000864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877826000864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:05:58Z","timestamp":1785881158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877826000864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S2212877826000864"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2026.102402","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2026.102402","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102402"}}